Showing 742 results
-
Story /Boston University developed a methodology to evaluate the impact of Novartis Access in Kenya. Peter C. Rockers tells us about the ongoing study.
-
Pulse Update /
-
In The News /An editorial by Harald Nusser, Head Novartis Access & Malaria Initiative, in DEVEX
-
In The News /A Medium post by Steve Davis, CEO of PATH
-
Media Library / -
Clinical Trials /
-
Press release /Sandoz proposed biosimilar adalimumab (GP2017) shown to have equivalent efficacy and a similar safety profile as reference medicine, Humira®*Comprehensive development program show potential of GP2017…
-
Ad hoc release /One-time treatment with Zolgensma (onasemnogene abeparvovec-xioi) is designed to replace lifetime of chronic therapy for all pediatric patients with SMA Annualized cost of Zolgensma is USD…
-
Press release /Ph 3 STR1VE data show prolonged event-free survival, early and rapid increases in CHOP-INTEND and significant milestone achievement in SMA Type 1, consistent with START trial First-in-human…
-
Press release /EU approval is based on two Phase III studies showing Cosentyx® provides fast and strong skin clearance, along with significant improvement in quality of life and a favorable safety profile1 …